Aging and sex hormones in males

Decaroli, Maria Chiara; Rochira, Vincenzo

doi:10.1080/21505594.2016.1259053

Cited by 105 publications

(82 citation statements)

References 202 publications

(444 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients with a poor general health status (malnourished, obese or chronic illnesses) may develop hypogonadism as a consequence of such conditions, and restoration to normal serum testosterone might be associated with increased risk of side effects, including major adverse cardiovascular events (Corona et al ., ; Decaroli & Rochira, ).…”

Section: Safety Considerationsmentioning

confidence: 97%

A new 2% testosterone gel formulation: a comparison with currently available topical preparations

Arver

Stief

Rosette³

et al. 2018

Andrology

View full text Add to dashboard Cite

Testosterone gel formulations have become a popular testosterone replacement therapy in patients with hypogonadism since their advent in the year 2000. The gel formulations restore testosterone levels to mid-normal physiological levels (14-17.5 nmol/L) as early as within 24 h, and help alleviate the signs and symptoms of testosterone deficiency, thereby leading to an improved quality of life. Although testosterone gels have a favourable efficacy and safety profile as compared to injectable and patch formulations, risk of secondary exposure poses a challenge. Approved testosterone topical formulations include Tostrex (Tostran , Fortesta ), Androgel (Testogel ), Testim and Axiron (solution), which have a favourable efficacy profile and positively impacted patient-reported outcome(s). Besides, Testavan, which is a 2% testosterone gel, is under registration in Europe and already approved in Australia in May 2017. Testavan uses a novel hydroalcoholic and highly viscous topical formulation. This product comes with a metered dose dispenser and a cap applicator that allows a hands-free application for precise dispensing and application. The present article provides a comprehensive review of pharmacokinetic, tolerability and safety profile of the testosterone gels available in the market along with the new 2% testosterone gel, Testavan.

show abstract

Section: Safety Considerationsmentioning

confidence: 97%

A new 2% testosterone gel formulation: a comparison with currently available topical preparations

Arver

Stief

Rosette³

et al. 2018

Andrology

View full text Add to dashboard Cite

show abstract

“…Serum TT and SHBG levels were measured by a chemiluminescent immunoassay (Beckman Coulter Inc., CA, USA) using a Beckman DXI 800 Analysis System (Fullerton, CA, USA). The levels of FT were calculated from TT, SHBG and albumin using a simple formula and a calculator widely available on the web (http://www.issam.ch/freetesto.htm) (Decaroli & Rochira, ). EMAS has recently defined diagnostic criteria for LOH to include the simultaneous presence of reproducibly low serum T (total T < 11 nmol/L and free T < 220 pmol/L) and three sexual symptoms (erectile dysfunction, and reduced frequency of sexual thoughts and morning erections) (Wu et al., ).…”

Section: Methodsmentioning

confidence: 99%

Risk factors for late-onset hypogonadism

Yang

et al. 2018

Andrologia

View full text Add to dashboard Cite

The European Male Aging Study (EMAS) has recently defined strict diagnostic criteria for late-onset hypogonadism (LOH) including the levels of serum total testosterone (TT), free testosterone (FT) and three sexual symptoms. However, there is no report on risk factors for LOH using these criteria. In this study, we investigated risk factors for LOH based on these criteria. We recruited 277 men (aged 36-80 years) who completed both a health check-up and two questionnaires (a health and lifestyle questionnaire, and a sexual function questionnaire). Data on parameters, such as systolic blood pressure (SBP), glucose, triglyceride (TG) and high-density lipoprotein (HDL), were obtained from medical records of the hospital in Shantou. TT and sex hormone-binding globulin (SHBG) were measured by chemiluminescent immunoassay, and FT was calculated. TT, FT, age, waist circumference, SBP and glucose showed significant differences between LOH-positive and LOH-negative individuals. Univariate regression analyses showed that age, waist circumference, SBP, glucose and health status were risk factors for LOH. Pearson's correlation analysis revealed that TT was inversely correlated with waist circumference, glucose and SBP, and FT was inversely correlated with age, SBP and health status. In conclusion, age, waist circumference, SBP, glucose and health status were risk factors for LOH.

show abstract

“…22 Post-menopausal women typically have serum estradiol levels below 15 pg/mL (60 pM). 21 Healthy men under age 55 average serum estradiol levels less than 40 pg/mL (150 pM), 21; 23; 24 and these levels decrease as men age and their testosterone levels decrease. 24 Average serum levels of estradiol achieved by ERT typically range from 20-100 pg/mL.…”

Section: Introductionmentioning

confidence: 99%

“…21 Healthy men under age 55 average serum estradiol levels less than 40 pg/mL (150 pM), 21; 23; 24 and these levels decrease as men age and their testosterone levels decrease. 24 Average serum levels of estradiol achieved by ERT typically range from 20-100 pg/mL. 25 Less data is available on synovial fluid (SF) estradiol levels, which is the most pertinent data for tissues such as the meniscus.…”

Section: Introductionmentioning

confidence: 99%

Transcriptome Sequencing Reveals Sex Differences in Human Meniscal Cell Response to Estrogen Based on Dosing Kinetics

Knewtson

Flores

Pacicca

et al. 2020

Preprint

View full text Add to dashboard Cite

Osteoarthritis is a disease marked by progressive and irreversible hyaline cartilage 25 and fibrocartilage breakdown that affects the lives of millions of patients worldwide. Female sex 26 and menopause are both risk factors for knee osteoarthritis, indicating that estrogen could play a 27 role in this disease. In this study, RNA sequencing was used to determine the effects of estrogen 28 treatment on human meniscal cells. Differences in the number and type of differentially expressed 29 genes were seen based on donor sex, estrogen dose, and dosing kinetics. Significantly more 30 differentially expressed genes were seen from male meniscal cells in response to all dosing 31 conditions compared to female cells. Importantly, more genes were differentially expressed in cells 32 treated with continuous dosing of estrogen, which has been shown to stimulate genomic estrogen 33 signaling, as compared to pulsed dosing. Additionally, functional enrichment analysis revealed 34 that many genes of the extracellular matrix, which is important for joint health and injury repair, 35were differentially expressed. Overall, this initial study lays the groundwork for future avenues to 36 pursue the effect of estrogen delivery on regenerative pathways. This critical analysis will then 37 inform the design and implementation of estrogen replacement therapies to promote meniscal 38 health and reduce the onset of osteoarthritis. 39 40

show abstract

Aging and sex hormones in males

Cited by 105 publications

References 202 publications

A new 2% testosterone gel formulation: a comparison with currently available topical preparations

A new 2% testosterone gel formulation: a comparison with currently available topical preparations

Risk factors for late-onset hypogonadism

Transcriptome Sequencing Reveals Sex Differences in Human Meniscal Cell Response to Estrogen Based on Dosing Kinetics

Contact Info

Product

Resources

About